nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—psoriasis	0.426	1	CrCtD
Pralatrexate—SLC19A1—Methotrexate—psoriasis	0.108	0.426	CbGbCtD
Pralatrexate—FPGS—Methotrexate—psoriasis	0.078	0.308	CbGbCtD
Pralatrexate—Pemetrexed—Methotrexate—psoriasis	0.0562	0.2	CrCrCtD
Pralatrexate—Raltitrexed—Methotrexate—psoriasis	0.0562	0.2	CrCrCtD
Pralatrexate—Folic Acid—Methotrexate—psoriasis	0.0562	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—psoriasis	0.0562	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—psoriasis	0.0562	0.2	CrCrCtD
Pralatrexate—DHFR—Methotrexate—psoriasis	0.0396	0.157	CbGbCtD
Pralatrexate—TYMS—Methotrexate—psoriasis	0.0276	0.109	CbGbCtD
Pralatrexate—SLC19A1—Folate Metabolism—CAT—psoriasis	0.000248	0.0568	CbGpPWpGaD
Pralatrexate—TYMS—Vitamin A—Acitretin—psoriasis	0.000231	0.113	CbGdCrCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL4—psoriasis	0.000228	0.0521	CbGpPWpGaD
Pralatrexate—DHFR—G1/S-Specific Transcription—PCNA—psoriasis	0.000225	0.0514	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—CRP—psoriasis	0.000197	0.0451	CbGpPWpGaD
Pralatrexate—TYMS—G1/S-Specific Transcription—PCNA—psoriasis	0.000196	0.0449	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—ICAM1—psoriasis	0.000181	0.0414	CbGpPWpGaD
Pralatrexate—TYMS—Isotretinoin—Acitretin—psoriasis	0.000162	0.0791	CbGdCrCtD
Pralatrexate—TYMS—Tretinoin—Acitretin—psoriasis	0.000162	0.0791	CbGdCrCtD
Pralatrexate—TYMS—Alitretinoin—Acitretin—psoriasis	0.000162	0.0791	CbGdCrCtD
Pralatrexate—Rash—Beclomethasone—psoriasis	0.000158	0.00464	CcSEcCtD
Pralatrexate—Dermatitis—Beclomethasone—psoriasis	0.000158	0.00464	CcSEcCtD
Pralatrexate—Rash—Fluocinonide—psoriasis	0.000156	0.0046	CcSEcCtD
Pralatrexate—Dermatitis—Fluocinonide—psoriasis	0.000156	0.0046	CcSEcCtD
Pralatrexate—Oedema—Acitretin—psoriasis	0.000155	0.00457	CcSEcCtD
Pralatrexate—Oedema—Fluocinolone Acetonide—psoriasis	0.000155	0.00455	CcSEcCtD
Pralatrexate—Body temperature increased—Methoxsalen—psoriasis	0.000155	0.00455	CcSEcCtD
Pralatrexate—Dehydration—Mycophenolate mofetil—psoriasis	0.000152	0.00448	CcSEcCtD
Pralatrexate—Decreased appetite—Calcitriol—psoriasis	0.000152	0.00446	CcSEcCtD
Pralatrexate—Liver function test abnormal—Mycophenolate mofetil—psoriasis	0.000151	0.00445	CcSEcCtD
Pralatrexate—Epistaxis—Mycophenolic acid—psoriasis	0.000151	0.00444	CcSEcCtD
Pralatrexate—Constipation—Calcitriol—psoriasis	0.000149	0.00439	CcSEcCtD
Pralatrexate—Hypokalaemia—Mycophenolate mofetil—psoriasis	0.000149	0.00439	CcSEcCtD
Pralatrexate—Nausea—Beclomethasone—psoriasis	0.000149	0.00437	CcSEcCtD
Pralatrexate—Anorexia—Acitretin—psoriasis	0.000148	0.00435	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Calcitriol—psoriasis	0.000143	0.0042	CcSEcCtD
Pralatrexate—Pruritus—Methoxsalen—psoriasis	0.000138	0.00407	CcSEcCtD
Pralatrexate—Anaemia—Hydroxyurea—psoriasis	0.000138	0.00406	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IFNG—psoriasis	0.000138	0.0315	CbGpPWpGaD
Pralatrexate—Body temperature increased—Calcitriol—psoriasis	0.000138	0.00406	CcSEcCtD
Pralatrexate—Abdominal pain—Calcitriol—psoriasis	0.000138	0.00406	CcSEcCtD
Pralatrexate—Hypokalaemia—Hydrocortisone—psoriasis	0.000136	0.004	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Cyclosporine—psoriasis	0.000135	0.00397	CcSEcCtD
Pralatrexate—Decreased appetite—Acitretin—psoriasis	0.000135	0.00397	CcSEcCtD
Pralatrexate—Pancytopenia—Mycophenolate mofetil—psoriasis	0.000134	0.00396	CcSEcCtD
Pralatrexate—Fatigue—Acitretin—psoriasis	0.000134	0.00394	CcSEcCtD
Pralatrexate—Leukopenia—Hydroxyurea—psoriasis	0.000134	0.00393	CcSEcCtD
Pralatrexate—Sepsis—Prednisone—psoriasis	0.000133	0.00391	CcSEcCtD
Pralatrexate—Constipation—Acitretin—psoriasis	0.000133	0.0039	CcSEcCtD
Pralatrexate—Neutropenia—Mycophenolate mofetil—psoriasis	0.000132	0.0039	CcSEcCtD
Pralatrexate—DHFR—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.000132	0.0302	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Acitretin—psoriasis	0.000127	0.00373	CcSEcCtD
Pralatrexate—Asthenia—Calcitriol—psoriasis	0.000125	0.00368	CcSEcCtD
Pralatrexate—Pruritus—Calcitriol—psoriasis	0.000123	0.00363	CcSEcCtD
Pralatrexate—Rash—Methoxsalen—psoriasis	0.000123	0.00363	CcSEcCtD
Pralatrexate—Dermatitis—Methoxsalen—psoriasis	0.000123	0.00363	CcSEcCtD
Pralatrexate—Abdominal pain—Acitretin—psoriasis	0.000123	0.00361	CcSEcCtD
Pralatrexate—Body temperature increased—Acitretin—psoriasis	0.000123	0.00361	CcSEcCtD
Pralatrexate—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000122	0.0036	CcSEcCtD
Pralatrexate—Epistaxis—Cyclosporine—psoriasis	0.000122	0.00359	CcSEcCtD
Pralatrexate—Oedema—Hydroxyurea—psoriasis	0.000122	0.00358	CcSEcCtD
Pralatrexate—Back pain—Mycophenolic acid—psoriasis	0.000121	0.00356	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Hydrocortisone—psoriasis	0.00012	0.00353	CcSEcCtD
Pralatrexate—Diarrhoea—Calcitriol—psoriasis	0.000119	0.00351	CcSEcCtD
Pralatrexate—Thrombocytopenia—Hydroxyurea—psoriasis	0.000119	0.00351	CcSEcCtD
Pralatrexate—Epistaxis—Mycophenolate mofetil—psoriasis	0.000119	0.0035	CcSEcCtD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—psoriasis	0.000116	0.0266	CbGpPWpGaD
Pralatrexate—Nausea—Methoxsalen—psoriasis	0.000116	0.00342	CcSEcCtD
Pralatrexate—Anorexia—Hydroxyurea—psoriasis	0.000116	0.00342	CcSEcCtD
Pralatrexate—Hypokalaemia—Dexamethasone—psoriasis	0.000116	0.00341	CcSEcCtD
Pralatrexate—Hypokalaemia—Betamethasone—psoriasis	0.000116	0.00341	CcSEcCtD
Pralatrexate—Anaemia—Mycophenolic acid—psoriasis	0.000115	0.0034	CcSEcCtD
Pralatrexate—TYMS—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.000115	0.0264	CbGpPWpGaD
Pralatrexate—SLC19A1—Folate Metabolism—NFKB1—psoriasis	0.000115	0.0262	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Triamcinolone—psoriasis	0.000113	0.00332	CcSEcCtD
Pralatrexate—Leukopenia—Mycophenolic acid—psoriasis	0.000112	0.00329	CcSEcCtD
Pralatrexate—Asthenia—Acitretin—psoriasis	0.000111	0.00328	CcSEcCtD
Pralatrexate—Sepsis—Methotrexate—psoriasis	0.000111	0.00326	CcSEcCtD
Pralatrexate—Vomiting—Calcitriol—psoriasis	0.000111	0.00326	CcSEcCtD
Pralatrexate—Rash—Calcitriol—psoriasis	0.00011	0.00324	CcSEcCtD
Pralatrexate—Dermatitis—Calcitriol—psoriasis	0.00011	0.00323	CcSEcCtD
Pralatrexate—Pruritus—Acitretin—psoriasis	0.00011	0.00323	CcSEcCtD
Pralatrexate—Pruritus—Fluocinolone Acetonide—psoriasis	0.000109	0.00322	CcSEcCtD
Pralatrexate—Cough—Mycophenolic acid—psoriasis	0.000109	0.00321	CcSEcCtD
Pralatrexate—Dyspnoea—Hydroxyurea—psoriasis	0.000109	0.0032	CcSEcCtD
Pralatrexate—Diarrhoea—Acitretin—psoriasis	0.000106	0.00312	CcSEcCtD
Pralatrexate—Decreased appetite—Hydroxyurea—psoriasis	0.000106	0.00312	CcSEcCtD
Pralatrexate—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000106	0.00312	CcSEcCtD
Pralatrexate—Fatigue—Hydroxyurea—psoriasis	0.000105	0.00309	CcSEcCtD
Pralatrexate—Constipation—Hydroxyurea—psoriasis	0.000104	0.00307	CcSEcCtD
Pralatrexate—Nausea—Calcitriol—psoriasis	0.000104	0.00305	CcSEcCtD
Pralatrexate—Epistaxis—Triamcinolone—psoriasis	0.000102	0.00301	CcSEcCtD
Pralatrexate—Oedema—Mycophenolic acid—psoriasis	0.000102	0.003	CcSEcCtD
Pralatrexate—Hypokalaemia—Prednisone—psoriasis	0.000101	0.00297	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mycophenolic acid—psoriasis	9.98e-05	0.00294	CcSEcCtD
Pralatrexate—Tachycardia—Mycophenolic acid—psoriasis	9.95e-05	0.00293	CcSEcCtD
Pralatrexate—Vomiting—Acitretin—psoriasis	9.86e-05	0.0029	CcSEcCtD
Pralatrexate—Vomiting—Fluocinolone Acetonide—psoriasis	9.83e-05	0.00289	CcSEcCtD
Pralatrexate—Rash—Acitretin—psoriasis	9.78e-05	0.00288	CcSEcCtD
Pralatrexate—Dermatitis—Acitretin—psoriasis	9.77e-05	0.00288	CcSEcCtD
Pralatrexate—Rash—Fluocinolone Acetonide—psoriasis	9.75e-05	0.00287	CcSEcCtD
Pralatrexate—Dermatitis—Fluocinolone Acetonide—psoriasis	9.74e-05	0.00287	CcSEcCtD
Pralatrexate—Anorexia—Mycophenolic acid—psoriasis	9.72e-05	0.00286	CcSEcCtD
Pralatrexate—Body temperature increased—Hydroxyurea—psoriasis	9.62e-05	0.00283	CcSEcCtD
Pralatrexate—Back pain—Mycophenolate mofetil—psoriasis	9.54e-05	0.00281	CcSEcCtD
Pralatrexate—Anaemia—Cyclosporine—psoriasis	9.34e-05	0.00275	CcSEcCtD
Pralatrexate—Nausea—Acitretin—psoriasis	9.21e-05	0.00271	CcSEcCtD
Pralatrexate—Nausea—Fluocinolone Acetonide—psoriasis	9.18e-05	0.0027	CcSEcCtD
Pralatrexate—Anaemia—Mycophenolate mofetil—psoriasis	9.11e-05	0.00268	CcSEcCtD
Pralatrexate—Dyspnoea—Mycophenolic acid—psoriasis	9.09e-05	0.00268	CcSEcCtD
Pralatrexate—Leukopenia—Cyclosporine—psoriasis	9.05e-05	0.00266	CcSEcCtD
Pralatrexate—Neutropenia—Prednisone—psoriasis	8.97e-05	0.00264	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TNF—psoriasis	8.92e-05	0.0204	CbGpPWpGaD
Pralatrexate—Decreased appetite—Mycophenolic acid—psoriasis	8.86e-05	0.00261	CcSEcCtD
Pralatrexate—Leukopenia—Mycophenolate mofetil—psoriasis	8.82e-05	0.0026	CcSEcCtD
Pralatrexate—Cough—Cyclosporine—psoriasis	8.82e-05	0.0026	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—CAT—psoriasis	8.81e-05	0.0202	CbGpPWpGaD
Pralatrexate—Fatigue—Mycophenolic acid—psoriasis	8.79e-05	0.00259	CcSEcCtD
Pralatrexate—Asthenia—Hydroxyurea—psoriasis	8.73e-05	0.00257	CcSEcCtD
Pralatrexate—Constipation—Mycophenolic acid—psoriasis	8.72e-05	0.00257	CcSEcCtD
Pralatrexate—Cough—Mycophenolate mofetil—psoriasis	8.6e-05	0.00253	CcSEcCtD
Pralatrexate—Liver function test abnormal—Methotrexate—psoriasis	8.56e-05	0.00252	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—psoriasis	8.35e-05	0.00246	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Mycophenolic acid—psoriasis	8.34e-05	0.00245	CcSEcCtD
Pralatrexate—Diarrhoea—Hydroxyurea—psoriasis	8.33e-05	0.00245	CcSEcCtD
Pralatrexate—Oedema—Cyclosporine—psoriasis	8.25e-05	0.00243	CcSEcCtD
Pralatrexate—Back pain—Triamcinolone—psoriasis	8.18e-05	0.00241	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IL4—psoriasis	8.1e-05	0.0185	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Cyclosporine—psoriasis	8.08e-05	0.00238	CcSEcCtD
Pralatrexate—Abdominal pain—Mycophenolic acid—psoriasis	8.06e-05	0.00237	CcSEcCtD
Pralatrexate—Body temperature increased—Mycophenolic acid—psoriasis	8.06e-05	0.00237	CcSEcCtD
Pralatrexate—Oedema—Mycophenolate mofetil—psoriasis	8.05e-05	0.00237	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mycophenolate mofetil—psoriasis	7.88e-05	0.00232	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—psoriasis	7.86e-05	0.018	CbGpPWpGaD
Pralatrexate—Anorexia—Cyclosporine—psoriasis	7.86e-05	0.00232	CcSEcCtD
Pralatrexate—Tachycardia—Mycophenolate mofetil—psoriasis	7.85e-05	0.00231	CcSEcCtD
Pralatrexate—Vomiting—Hydroxyurea—psoriasis	7.74e-05	0.00228	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—NDUFA5—psoriasis	7.72e-05	0.0177	CbGpPWpGaD
Pralatrexate—Rash—Hydroxyurea—psoriasis	7.68e-05	0.00226	CcSEcCtD
Pralatrexate—Anorexia—Mycophenolate mofetil—psoriasis	7.67e-05	0.00226	CcSEcCtD
Pralatrexate—Dermatitis—Hydroxyurea—psoriasis	7.67e-05	0.00226	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—psoriasis	7.61e-05	0.00224	CcSEcCtD
Pralatrexate—Oedema—Prednisolone—psoriasis	7.51e-05	0.00221	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—psoriasis	7.5e-05	0.00221	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—psoriasis	7.45e-05	0.00219	CcSEcCtD
Pralatrexate—Cough—Triamcinolone—psoriasis	7.38e-05	0.00217	CcSEcCtD
Pralatrexate—Dyspnoea—Cyclosporine—psoriasis	7.35e-05	0.00217	CcSEcCtD
Pralatrexate—Oedema—Hydrocortisone—psoriasis	7.33e-05	0.00216	CcSEcCtD
Pralatrexate—Tachycardia—Prednisolone—psoriasis	7.33e-05	0.00216	CcSEcCtD
Pralatrexate—Asthenia—Mycophenolic acid—psoriasis	7.31e-05	0.00215	CcSEcCtD
Pralatrexate—Nausea—Hydroxyurea—psoriasis	7.23e-05	0.00213	CcSEcCtD
Pralatrexate—Pruritus—Mycophenolic acid—psoriasis	7.21e-05	0.00212	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL6—psoriasis	7.2e-05	0.0165	CbGpPWpGaD
Pralatrexate—Dyspnoea—Mycophenolate mofetil—psoriasis	7.17e-05	0.00211	CcSEcCtD
Pralatrexate—Decreased appetite—Cyclosporine—psoriasis	7.17e-05	0.00211	CcSEcCtD
Pralatrexate—Tachycardia—Hydrocortisone—psoriasis	7.15e-05	0.00211	CcSEcCtD
Pralatrexate—Fatigue—Cyclosporine—psoriasis	7.11e-05	0.00209	CcSEcCtD
Pralatrexate—Constipation—Cyclosporine—psoriasis	7.05e-05	0.00208	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—CRP—psoriasis	7e-05	0.016	CbGpPWpGaD
Pralatrexate—Decreased appetite—Mycophenolate mofetil—psoriasis	6.99e-05	0.00206	CcSEcCtD
Pralatrexate—Anorexia—Hydrocortisone—psoriasis	6.99e-05	0.00206	CcSEcCtD
Pralatrexate—Diarrhoea—Mycophenolic acid—psoriasis	6.98e-05	0.00205	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.95e-05	0.0159	CbGpPWpGaD
Pralatrexate—Oedema—Triamcinolone—psoriasis	6.9e-05	0.00203	CcSEcCtD
Pralatrexate—Constipation—Mycophenolate mofetil—psoriasis	6.88e-05	0.00203	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Cyclosporine—psoriasis	6.74e-05	0.00199	CcSEcCtD
Pralatrexate—Epistaxis—Methotrexate—psoriasis	6.74e-05	0.00198	CcSEcCtD
Pralatrexate—Tachycardia—Triamcinolone—psoriasis	6.74e-05	0.00198	CcSEcCtD
Pralatrexate—TYMS—Nucleotide metabolism—CAT—psoriasis	6.73e-05	0.0154	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.58e-05	0.00194	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CYP2S1—psoriasis	6.57e-05	0.015	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—NDUFA5—psoriasis	6.57e-05	0.015	CbGpPWpGaD
Pralatrexate—Body temperature increased—Cyclosporine—psoriasis	6.52e-05	0.00192	CcSEcCtD
Pralatrexate—Abdominal pain—Cyclosporine—psoriasis	6.52e-05	0.00192	CcSEcCtD
Pralatrexate—Vomiting—Mycophenolic acid—psoriasis	6.48e-05	0.00191	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—ICAM1—psoriasis	6.43e-05	0.0147	CbGpPWpGaD
Pralatrexate—Rash—Mycophenolic acid—psoriasis	6.43e-05	0.00189	CcSEcCtD
Pralatrexate—Dermatitis—Mycophenolic acid—psoriasis	6.42e-05	0.00189	CcSEcCtD
Pralatrexate—Decreased appetite—Hydrocortisone—psoriasis	6.37e-05	0.00188	CcSEcCtD
Pralatrexate—Abdominal pain—Mycophenolate mofetil—psoriasis	6.36e-05	0.00187	CcSEcCtD
Pralatrexate—Body temperature increased—Mycophenolate mofetil—psoriasis	6.36e-05	0.00187	CcSEcCtD
Pralatrexate—Fatigue—Hydrocortisone—psoriasis	6.32e-05	0.00186	CcSEcCtD
Pralatrexate—Oedema—Dexamethasone—psoriasis	6.26e-05	0.00184	CcSEcCtD
Pralatrexate—Oedema—Betamethasone—psoriasis	6.26e-05	0.00184	CcSEcCtD
Pralatrexate—Anaemia—Prednisone—psoriasis	6.18e-05	0.00182	CcSEcCtD
Pralatrexate—Dyspnoea—Triamcinolone—psoriasis	6.15e-05	0.00181	CcSEcCtD
Pralatrexate—Thrombocytopenia—Betamethasone—psoriasis	6.13e-05	0.00181	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dexamethasone—psoriasis	6.13e-05	0.00181	CcSEcCtD
Pralatrexate—Tachycardia—Dexamethasone—psoriasis	6.11e-05	0.0018	CcSEcCtD
Pralatrexate—Tachycardia—Betamethasone—psoriasis	6.11e-05	0.0018	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	6.09e-05	0.0139	CbGpPWpGaD
Pralatrexate—Nausea—Mycophenolic acid—psoriasis	6.06e-05	0.00178	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Hydrocortisone—psoriasis	5.99e-05	0.00177	CcSEcCtD
Pralatrexate—Anorexia—Dexamethasone—psoriasis	5.97e-05	0.00176	CcSEcCtD
Pralatrexate—Anorexia—Betamethasone—psoriasis	5.97e-05	0.00176	CcSEcCtD
Pralatrexate—Fatigue—Triamcinolone—psoriasis	5.95e-05	0.00175	CcSEcCtD
Pralatrexate—Asthenia—Cyclosporine—psoriasis	5.92e-05	0.00174	CcSEcCtD
Pralatrexate—Pruritus—Cyclosporine—psoriasis	5.84e-05	0.00172	CcSEcCtD
Pralatrexate—Abdominal pain—Hydrocortisone—psoriasis	5.79e-05	0.00171	CcSEcCtD
Pralatrexate—Body temperature increased—Hydrocortisone—psoriasis	5.79e-05	0.00171	CcSEcCtD
Pralatrexate—Asthenia—Mycophenolate mofetil—psoriasis	5.77e-05	0.0017	CcSEcCtD
Pralatrexate—Pruritus—Mycophenolate mofetil—psoriasis	5.69e-05	0.00168	CcSEcCtD
Pralatrexate—Diarrhoea—Cyclosporine—psoriasis	5.64e-05	0.00166	CcSEcCtD
Pralatrexate—FPGS—Metabolism—CYP2S1—psoriasis	5.58e-05	0.0128	CbGpPWpGaD
Pralatrexate—Diarrhoea—Mycophenolate mofetil—psoriasis	5.51e-05	0.00162	CcSEcCtD
Pralatrexate—Body temperature increased—Triamcinolone—psoriasis	5.46e-05	0.00161	CcSEcCtD
Pralatrexate—Oedema—Prednisone—psoriasis	5.45e-05	0.00161	CcSEcCtD
Pralatrexate—Decreased appetite—Betamethasone—psoriasis	5.44e-05	0.0016	CcSEcCtD
Pralatrexate—Decreased appetite—Dexamethasone—psoriasis	5.44e-05	0.0016	CcSEcCtD
Pralatrexate—Back pain—Methotrexate—psoriasis	5.4e-05	0.00159	CcSEcCtD
Pralatrexate—Fatigue—Betamethasone—psoriasis	5.4e-05	0.00159	CcSEcCtD
Pralatrexate—Fatigue—Dexamethasone—psoriasis	5.4e-05	0.00159	CcSEcCtD
Pralatrexate—Tachycardia—Prednisone—psoriasis	5.32e-05	0.00157	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	5.31e-05	0.0122	CbGpPWpGaD
Pralatrexate—Asthenia—Hydrocortisone—psoriasis	5.26e-05	0.00155	CcSEcCtD
Pralatrexate—Vomiting—Cyclosporine—psoriasis	5.24e-05	0.00154	CcSEcCtD
Pralatrexate—Rash—Cyclosporine—psoriasis	5.2e-05	0.00153	CcSEcCtD
Pralatrexate—Anorexia—Prednisone—psoriasis	5.2e-05	0.00153	CcSEcCtD
Pralatrexate—Dermatitis—Cyclosporine—psoriasis	5.2e-05	0.00153	CcSEcCtD
Pralatrexate—Pruritus—Hydrocortisone—psoriasis	5.19e-05	0.00153	CcSEcCtD
Pralatrexate—Anaemia—Methotrexate—psoriasis	5.16e-05	0.00152	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Betamethasone—psoriasis	5.12e-05	0.00151	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dexamethasone—psoriasis	5.12e-05	0.00151	CcSEcCtD
Pralatrexate—Vomiting—Mycophenolate mofetil—psoriasis	5.12e-05	0.00151	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—PCNA—psoriasis	5.09e-05	0.0116	CbGpPWpGaD
Pralatrexate—Rash—Mycophenolate mofetil—psoriasis	5.07e-05	0.00149	CcSEcCtD
Pralatrexate—Dermatitis—Mycophenolate mofetil—psoriasis	5.07e-05	0.00149	CcSEcCtD
Pralatrexate—Diarrhoea—Hydrocortisone—psoriasis	5.02e-05	0.00148	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—psoriasis	5e-05	0.00147	CcSEcCtD
Pralatrexate—Asthenia—Triamcinolone—psoriasis	4.95e-05	0.00146	CcSEcCtD
Pralatrexate—Body temperature increased—Dexamethasone—psoriasis	4.95e-05	0.00146	CcSEcCtD
Pralatrexate—Abdominal pain—Betamethasone—psoriasis	4.95e-05	0.00146	CcSEcCtD
Pralatrexate—Body temperature increased—Betamethasone—psoriasis	4.95e-05	0.00146	CcSEcCtD
Pralatrexate—Abdominal pain—Dexamethasone—psoriasis	4.95e-05	0.00146	CcSEcCtD
Pralatrexate—Nausea—Cyclosporine—psoriasis	4.9e-05	0.00144	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IFNG—psoriasis	4.9e-05	0.0112	CbGpPWpGaD
Pralatrexate—Pruritus—Triamcinolone—psoriasis	4.88e-05	0.00144	CcSEcCtD
Pralatrexate—Cough—Methotrexate—psoriasis	4.87e-05	0.00144	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—psoriasis	4.86e-05	0.0111	CbGpPWpGaD
Pralatrexate—TYMS—Triamcinolone—Clobetasol propionate—psoriasis	4.83e-05	0.0236	CbGdCrCtD
Pralatrexate—Nausea—Mycophenolate mofetil—psoriasis	4.78e-05	0.00141	CcSEcCtD
Pralatrexate—Decreased appetite—Prednisone—psoriasis	4.74e-05	0.0014	CcSEcCtD
Pralatrexate—Rash—Prednisolone—psoriasis	4.73e-05	0.00139	CcSEcCtD
Pralatrexate—Dermatitis—Prednisolone—psoriasis	4.73e-05	0.00139	CcSEcCtD
Pralatrexate—TYMS—Fluticasone Propionate—Clobetasol propionate—psoriasis	4.71e-05	0.023	CbGdCrCtD
Pralatrexate—Fatigue—Prednisone—psoriasis	4.7e-05	0.00138	CcSEcCtD
Pralatrexate—Constipation—Prednisone—psoriasis	4.66e-05	0.00137	CcSEcCtD
Pralatrexate—Vomiting—Hydrocortisone—psoriasis	4.66e-05	0.00137	CcSEcCtD
Pralatrexate—Rash—Hydrocortisone—psoriasis	4.62e-05	0.00136	CcSEcCtD
Pralatrexate—Dermatitis—Hydrocortisone—psoriasis	4.62e-05	0.00136	CcSEcCtD
Pralatrexate—Asthenia—Dexamethasone—psoriasis	4.49e-05	0.00132	CcSEcCtD
Pralatrexate—Asthenia—Betamethasone—psoriasis	4.49e-05	0.00132	CcSEcCtD
Pralatrexate—Thrombocytopenia—Methotrexate—psoriasis	4.46e-05	0.00131	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Prednisone—psoriasis	4.46e-05	0.00131	CcSEcCtD
Pralatrexate—Nausea—Prednisolone—psoriasis	4.46e-05	0.00131	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Clobetasol propionate—psoriasis	4.45e-05	0.0218	CbGdCrCtD
Pralatrexate—TYMS—G1/S Transition—PCNA—psoriasis	4.44e-05	0.0101	CbGpPWpGaD
Pralatrexate—Pruritus—Betamethasone—psoriasis	4.43e-05	0.0013	CcSEcCtD
Pralatrexate—Pruritus—Dexamethasone—psoriasis	4.43e-05	0.0013	CcSEcCtD
Pralatrexate—Vomiting—Triamcinolone—psoriasis	4.39e-05	0.00129	CcSEcCtD
Pralatrexate—Nausea—Hydrocortisone—psoriasis	4.35e-05	0.00128	CcSEcCtD
Pralatrexate—Rash—Triamcinolone—psoriasis	4.35e-05	0.00128	CcSEcCtD
Pralatrexate—Dermatitis—Triamcinolone—psoriasis	4.35e-05	0.00128	CcSEcCtD
Pralatrexate—Anorexia—Methotrexate—psoriasis	4.34e-05	0.00128	CcSEcCtD
Pralatrexate—Abdominal pain—Prednisone—psoriasis	4.31e-05	0.00127	CcSEcCtD
Pralatrexate—Body temperature increased—Prednisone—psoriasis	4.31e-05	0.00127	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—PCNA—psoriasis	4.29e-05	0.0098	CbGpPWpGaD
Pralatrexate—Diarrhoea—Dexamethasone—psoriasis	4.28e-05	0.00126	CcSEcCtD
Pralatrexate—Diarrhoea—Betamethasone—psoriasis	4.28e-05	0.00126	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—psoriasis	4.24e-05	0.0097	CbGpPWpGaD
Pralatrexate—Nausea—Triamcinolone—psoriasis	4.1e-05	0.00121	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—NFKB1—psoriasis	4.07e-05	0.00931	CbGpPWpGaD
Pralatrexate—Dyspnoea—Methotrexate—psoriasis	4.06e-05	0.0012	CcSEcCtD
Pralatrexate—Vomiting—Betamethasone—psoriasis	3.98e-05	0.00117	CcSEcCtD
Pralatrexate—Vomiting—Dexamethasone—psoriasis	3.98e-05	0.00117	CcSEcCtD
Pralatrexate—Decreased appetite—Methotrexate—psoriasis	3.96e-05	0.00117	CcSEcCtD
Pralatrexate—TYMS—Clobetasol propionate—Beclomethasone—psoriasis	3.96e-05	0.0194	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Fluocinonide—psoriasis	3.96e-05	0.0194	CbGdCrCtD
Pralatrexate—Rash—Dexamethasone—psoriasis	3.95e-05	0.00116	CcSEcCtD
Pralatrexate—Rash—Betamethasone—psoriasis	3.95e-05	0.00116	CcSEcCtD
Pralatrexate—Dermatitis—Dexamethasone—psoriasis	3.95e-05	0.00116	CcSEcCtD
Pralatrexate—Dermatitis—Betamethasone—psoriasis	3.95e-05	0.00116	CcSEcCtD
Pralatrexate—Fatigue—Methotrexate—psoriasis	3.93e-05	0.00116	CcSEcCtD
Pralatrexate—Asthenia—Prednisone—psoriasis	3.91e-05	0.00115	CcSEcCtD
Pralatrexate—TYMS—Flunisolide—Fluocinonide—psoriasis	3.91e-05	0.0191	CbGdCrCtD
Pralatrexate—TYMS—Budesonide—Clobetasol propionate—psoriasis	3.9e-05	0.0191	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Fluocinonide—psoriasis	3.87e-05	0.0189	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Beclomethasone—psoriasis	3.87e-05	0.0189	CbGdCrCtD
Pralatrexate—Pruritus—Prednisone—psoriasis	3.86e-05	0.00114	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PTTG1—psoriasis	3.86e-05	0.00882	CbGpPWpGaD
Pralatrexate—TYMS—Clobetasol propionate—Fluocinolone Acetonide—psoriasis	3.85e-05	0.0188	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Fluocinolone Acetonide—psoriasis	3.8e-05	0.0186	CbGdCrCtD
Pralatrexate—TYMS—Fluticasone Propionate—Fluocinonide—psoriasis	3.77e-05	0.0184	CbGdCrCtD
Pralatrexate—TYMS—Fluticasone Propionate—Beclomethasone—psoriasis	3.77e-05	0.0184	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Fluocinolone Acetonide—psoriasis	3.76e-05	0.0184	CbGdCrCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—PCNA—psoriasis	3.74e-05	0.00855	CbGpPWpGaD
Pralatrexate—Diarrhoea—Prednisone—psoriasis	3.73e-05	0.0011	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Methotrexate—psoriasis	3.73e-05	0.0011	CcSEcCtD
Pralatrexate—Nausea—Dexamethasone—psoriasis	3.72e-05	0.0011	CcSEcCtD
Pralatrexate—Nausea—Betamethasone—psoriasis	3.72e-05	0.0011	CcSEcCtD
Pralatrexate—TYMS—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	3.67e-05	0.0179	CbGdCrCtD
Pralatrexate—Body temperature increased—Methotrexate—psoriasis	3.6e-05	0.00106	CcSEcCtD
Pralatrexate—Abdominal pain—Methotrexate—psoriasis	3.6e-05	0.00106	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Beclomethasone—psoriasis	3.57e-05	0.0174	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Fluocinonide—psoriasis	3.57e-05	0.0174	CbGdCrCtD
Pralatrexate—Vomiting—Prednisone—psoriasis	3.47e-05	0.00102	CcSEcCtD
Pralatrexate—TYMS—Diflorasone—Fluocinolone Acetonide—psoriasis	3.47e-05	0.0169	CbGdCrCtD
Pralatrexate—DHFR—Cell Cycle—PTTG1—psoriasis	3.45e-05	0.00788	CbGpPWpGaD
Pralatrexate—Rash—Prednisone—psoriasis	3.44e-05	0.00101	CcSEcCtD
Pralatrexate—Dermatitis—Prednisone—psoriasis	3.44e-05	0.00101	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PTTG1—psoriasis	3.36e-05	0.00769	CbGpPWpGaD
Pralatrexate—Asthenia—Methotrexate—psoriasis	3.27e-05	0.000963	CcSEcCtD
Pralatrexate—Nausea—Prednisone—psoriasis	3.24e-05	0.000954	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—psoriasis	3.22e-05	0.00095	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CARM1—psoriasis	3.21e-05	0.00733	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TNF—psoriasis	3.17e-05	0.00725	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Fluocinonide—psoriasis	3.13e-05	0.0153	CbGdCrCtD
Pralatrexate—TYMS—Budesonide—Beclomethasone—psoriasis	3.13e-05	0.0153	CbGdCrCtD
Pralatrexate—Diarrhoea—Methotrexate—psoriasis	3.12e-05	0.000918	CcSEcCtD
Pralatrexate—TYMS—Budesonide—Fluocinolone Acetonide—psoriasis	3.04e-05	0.0148	CbGdCrCtD
Pralatrexate—TYMS—Cell Cycle—PTTG1—psoriasis	3.01e-05	0.00688	CbGpPWpGaD
Pralatrexate—Vomiting—Methotrexate—psoriasis	2.9e-05	0.000853	CcSEcCtD
Pralatrexate—Rash—Methotrexate—psoriasis	2.87e-05	0.000846	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—psoriasis	2.87e-05	0.000846	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.83e-05	0.00648	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—psoriasis	2.79e-05	0.00639	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NDUFA5—psoriasis	2.74e-05	0.00627	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CARM1—psoriasis	2.73e-05	0.00624	CbGpPWpGaD
Pralatrexate—Nausea—Methotrexate—psoriasis	2.71e-05	0.000797	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IL6—psoriasis	2.56e-05	0.00585	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—LEP—psoriasis	2.45e-05	0.00561	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NDUFA5—psoriasis	2.39e-05	0.00547	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.38e-05	0.00544	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP2S1—psoriasis	2.33e-05	0.00533	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—NOS2—psoriasis	2.28e-05	0.00523	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—psoriasis	2.24e-05	0.00512	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—PPARG—psoriasis	2.14e-05	0.00488	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP2S1—psoriasis	2.04e-05	0.00465	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CAT—psoriasis	1.97e-05	0.00451	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HLA-A—psoriasis	1.96e-05	0.00448	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—psoriasis	1.95e-05	0.00447	CbGpPWpGaD
Pralatrexate—TYMS—Flunisolide—Hydrocortisone—psoriasis	1.92e-05	0.00938	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Hydrocortisone—psoriasis	1.9e-05	0.00928	CbGdCrCtD
Pralatrexate—SLC19A1—Disease—APOE—psoriasis	1.83e-05	0.00418	CbGpPWpGaD
Pralatrexate—TYMS—Clobetasol propionate—Betamethasone—psoriasis	1.81e-05	0.00882	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Dexamethasone—psoriasis	1.81e-05	0.00882	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Dexamethasone—psoriasis	1.78e-05	0.00871	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Betamethasone—psoriasis	1.78e-05	0.00871	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Triamcinolone—psoriasis	1.76e-05	0.00862	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Dexamethasone—psoriasis	1.76e-05	0.00862	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Betamethasone—psoriasis	1.76e-05	0.00862	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Triamcinolone—psoriasis	1.74e-05	0.00851	CbGdCrCtD
Pralatrexate—TYMS—Fluticasone Propionate—Betamethasone—psoriasis	1.72e-05	0.0084	CbGdCrCtD
Pralatrexate—TYMS—Fluticasone Propionate—Dexamethasone—psoriasis	1.72e-05	0.0084	CbGdCrCtD
Pralatrexate—SLC19A1—Disease—NOS2—psoriasis	1.71e-05	0.0039	CbGpPWpGaD
Pralatrexate—TYMS—Fluticasone Propionate—Triamcinolone—psoriasis	1.68e-05	0.00821	CbGdCrCtD
Pralatrexate—FPGS—Metabolism—CAT—psoriasis	1.68e-05	0.00384	CbGpPWpGaD
Pralatrexate—TYMS—Clobetasol propionate—Prednisone—psoriasis	1.67e-05	0.00818	CbGdCrCtD
Pralatrexate—FPGS—Disease—HLA-A—psoriasis	1.67e-05	0.00381	CbGpPWpGaD
Pralatrexate—TYMS—Flunisolide—Prednisone—psoriasis	1.65e-05	0.00807	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Prednisone—psoriasis	1.64e-05	0.00799	CbGdCrCtD
Pralatrexate—TYMS—Clobetasol propionate—Prednisolone—psoriasis	1.63e-05	0.00799	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Betamethasone—psoriasis	1.63e-05	0.00794	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Dexamethasone—psoriasis	1.63e-05	0.00794	CbGdCrCtD
Pralatrexate—TYMS—Flunisolide—Prednisolone—psoriasis	1.61e-05	0.00788	CbGdCrCtD
Pralatrexate—TYMS—Triamcinolone—Prednisolone—psoriasis	1.6e-05	0.0078	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Triamcinolone—psoriasis	1.59e-05	0.00776	CbGdCrCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.58e-05	0.00361	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PCNA—psoriasis	1.57e-05	0.00359	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APOE—psoriasis	1.56e-05	0.00356	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Hydrocortisone—psoriasis	1.53e-05	0.0075	CbGdCrCtD
Pralatrexate—SLC19A1—Metabolism—APOE—psoriasis	1.53e-05	0.0035	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.52e-05	0.00347	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—JUN—psoriasis	1.51e-05	0.00346	CbGpPWpGaD
Pralatrexate—TYMS—Diflorasone—Prednisone—psoriasis	1.51e-05	0.00737	CbGdCrCtD
Pralatrexate—TYMS—Diflorasone—Prednisolone—psoriasis	1.47e-05	0.00719	CbGdCrCtD
Pralatrexate—TYMS—Danazol—Hydrocortisone—psoriasis	1.47e-05	0.00719	CbGdCrCtD
Pralatrexate—FPGS—Disease—NOS2—psoriasis	1.45e-05	0.00332	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Dexamethasone—psoriasis	1.42e-05	0.00696	CbGdCrCtD
Pralatrexate—TYMS—Budesonide—Betamethasone—psoriasis	1.42e-05	0.00696	CbGdCrCtD
Pralatrexate—DHFR—Cell Cycle—PCNA—psoriasis	1.41e-05	0.00321	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TYK2—psoriasis	1.4e-05	0.00319	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Triamcinolone—psoriasis	1.39e-05	0.0068	CbGdCrCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.38e-05	0.00315	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PCNA—psoriasis	1.37e-05	0.00314	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PPARG—psoriasis	1.33e-05	0.00305	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Prednisone—psoriasis	1.32e-05	0.00646	CbGdCrCtD
Pralatrexate—FPGS—Metabolism—APOE—psoriasis	1.3e-05	0.00298	CbGpPWpGaD
Pralatrexate—TYMS—Budesonide—Prednisolone—psoriasis	1.29e-05	0.0063	CbGdCrCtD
Pralatrexate—TYMS—Danazol—Prednisone—psoriasis	1.27e-05	0.00619	CbGdCrCtD
Pralatrexate—SLC19A1—Disease—CD4—psoriasis	1.26e-05	0.00289	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PCNA—psoriasis	1.23e-05	0.0028	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TYK2—psoriasis	1.19e-05	0.00272	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.18e-05	0.0027	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CARM1—psoriasis	1.14e-05	0.0026	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PPARG—psoriasis	1.14e-05	0.0026	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CD4—psoriasis	1.07e-05	0.00246	CbGpPWpGaD
Pralatrexate—TYMS—Levonorgestrel—Hydrocortisone—psoriasis	1.05e-05	0.00515	CbGdCrCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.04e-05	0.00238	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—psoriasis	1e-05	0.00229	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CARM1—psoriasis	9.94e-06	0.00227	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—STAT3—psoriasis	9.78e-06	0.00224	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—IL6—psoriasis	9.15e-06	0.00209	CbGpPWpGaD
Pralatrexate—FPGS—Disease—STAT3—psoriasis	8.32e-06	0.0019	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CAT—psoriasis	7.01e-06	0.0016	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HLA-A—psoriasis	6.96e-06	0.00159	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IL6—psoriasis	6.83e-06	0.00156	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APOE—psoriasis	6.5e-06	0.00149	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CAT—psoriasis	6.11e-06	0.0014	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NOS2—psoriasis	6.06e-06	0.00139	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IL6—psoriasis	5.81e-06	0.00133	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—APOE—psoriasis	5.44e-06	0.00124	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—psoriasis	5.17e-06	0.00118	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TYK2—psoriasis	4.96e-06	0.00113	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—APOE—psoriasis	4.75e-06	0.00109	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPARG—psoriasis	4.74e-06	0.00108	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—psoriasis	4.51e-06	0.00103	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD4—psoriasis	4.49e-06	0.00103	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPARG—psoriasis	4.14e-06	0.000946	CbGpPWpGaD
Pralatrexate—DHFR—Disease—STAT3—psoriasis	3.47e-06	0.000794	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IL6—psoriasis	2.43e-06	0.000555	CbGpPWpGaD
